By Dr Brittney Harrington

Preprints

Lipkowitz S; Kudo K; Crooks D; Greer Y; Yang Y; Brender J; Yoshida T; Harrington B; Kamdar R; Korrapati S; Shibuya Y; Henegar L; Kopp J; Fujii T; Annunziata C, 2024, Targeting Metabolic Vulnerability by Combining NAMPT Inhibitors and Disulfiram for Treatment of Recurrent Ovarian Cancer, http://dx.doi.org/10.21203/rs.3.rs-4150814/v1

Annunziata C; Kudo K; Greer Y; Yoshida T; Harrington B; Korrapati S; Shibuya Y; Henegar L; Kopp J; Fujii T; Lipkowitz S, 2023, Dual-inhibition of NAMPT and PAK4 induces anti-tumor effects in 3D-spheroids model of platinum-resistant ovarian cancer, http://dx.doi.org/10.21203/rs.3.rs-3399502/v1

Harrington B; Kamdar R; Ning F; Korrapati S; Caminear M; Hernandez L; Butcher D; Edmondson E; Traficante N; Australian Ovarian Cancer Study Group ; Gough M; Rogers R; Lourie R; Shetty J; Tran B; Elloumi F; Abdelmaksoud A; Lal Nag M; Mazan-Mamczarz K; House C; Hooper J; Bowtell D; Annunziata C, 2022, UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer, http://dx.doi.org/10.1101/2022.10.07.509566

Kryza T; Khan T; Lovell S; Harrington B; Yin J; Porazinski S; Pajic M; Koistinen H; Rantala J; Dreyer T; Magdolen V; Reuning U; He Y; Tate E; Hooper JD, 2020, Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1, http://dx.doi.org/10.21203/rs.3.rs-92391/v1

Back to profile page